Durational Study of Persistent Transduction of Rhesus Macaque Lung and Other Organs Following Single Dosing with AAV1-CFTR.

IF 4.6 3区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Human gene therapy Pub Date : 2026-11-01 Epub Date: 2026-08-16 DOI:10.1177/10430342261478760
Prajita Paul, Tanvi Sharma, Masoud Afshani, Amanda Maxwell, Abhishek Sharma, William B Guggino, Liudmila Cebotaru
{"title":"Durational Study of Persistent Transduction of Rhesus Macaque Lung and Other Organs Following Single Dosing with AAV1-CFTR.","authors":"Prajita Paul, Tanvi Sharma, Masoud Afshani, Amanda Maxwell, Abhishek Sharma, William B Guggino, Liudmila Cebotaru","doi":"10.1177/10430342261478760","DOIUrl":null,"url":null,"abstract":"<p><p>Adeno-associated virus (AAV)-mediated gene transfer remains a promising strategy for cystic fibrosis (CF), but durability of expression and optimal dosing intervals are unresolved challenges. Here, we evaluated long-term gene transfer, transduction, and immunological responses following a single pulmonary administration of an AAV1 vector encoding Δ27-264 CFTR to juvenile rhesus macaques. Four animals received 1 × 10<sup>1</sup>³ vector genomes via endotracheal spray. Two were untreated. All were analyzed 180 days post-delivery. Vector genomes were detected throughout the conducting airways and distal lung at levels ranging from ∼5 × 10<sup>6</sup> to 9 × 10<sup>7</sup> vg/µg genomic DNA. Vector genomes were also detected in extrapulmonary tissues, including liver, pancreas, spleen, heart, and kidney. Cystic fibrosis transmembrane conductance regulator (CFTR) messenger RNA expression was detected in all tissues examined and in several respiratory and extrapulmonary tissues, accompanied by increased CFTR protein expression in multiple tissues. Transgene expression was observed in airway basal cells and FOXI1-positive ionocytes, indicating targeting of key epithelial and progenitor cell populations. Despite persistence of vector genomes, immune activation was limited. Cytokine and chemokine expression profiles showed only sporadic, tissue-specific changes without evidence of coordinated inflammation. Neutralizing antibodies to AAV1 developed in all animals but did not correlate with capsid-specific T cell responses, which remained low and infrequent. These findings indicate sustained gene transfer and transduction for at least 180 days following a single AAV1 administration to the primate lung, with minimal immunopathology. The durability of expression supports the potential feasibility of extended dosing intervals and informs the development of repeatable AAV-based gene therapies for CF.</p>","PeriodicalId":13007,"journal":{"name":"Human gene therapy","volume":" ","pages":"1056-1067"},"PeriodicalIF":4.6000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10430342261478760","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Adeno-associated virus (AAV)-mediated gene transfer remains a promising strategy for cystic fibrosis (CF), but durability of expression and optimal dosing intervals are unresolved challenges. Here, we evaluated long-term gene transfer, transduction, and immunological responses following a single pulmonary administration of an AAV1 vector encoding Δ27-264 CFTR to juvenile rhesus macaques. Four animals received 1 × 101³ vector genomes via endotracheal spray. Two were untreated. All were analyzed 180 days post-delivery. Vector genomes were detected throughout the conducting airways and distal lung at levels ranging from ∼5 × 106 to 9 × 107 vg/µg genomic DNA. Vector genomes were also detected in extrapulmonary tissues, including liver, pancreas, spleen, heart, and kidney. Cystic fibrosis transmembrane conductance regulator (CFTR) messenger RNA expression was detected in all tissues examined and in several respiratory and extrapulmonary tissues, accompanied by increased CFTR protein expression in multiple tissues. Transgene expression was observed in airway basal cells and FOXI1-positive ionocytes, indicating targeting of key epithelial and progenitor cell populations. Despite persistence of vector genomes, immune activation was limited. Cytokine and chemokine expression profiles showed only sporadic, tissue-specific changes without evidence of coordinated inflammation. Neutralizing antibodies to AAV1 developed in all animals but did not correlate with capsid-specific T cell responses, which remained low and infrequent. These findings indicate sustained gene transfer and transduction for at least 180 days following a single AAV1 administration to the primate lung, with minimal immunopathology. The durability of expression supports the potential feasibility of extended dosing intervals and informs the development of repeatable AAV-based gene therapies for CF.

单次给药AAV1-CFTR对恒河猴肺和其他器官持续转导的持续研究。
腺相关病毒(AAV)介导的基因转移仍然是治疗囊性纤维化(CF)的一种有希望的策略,但表达的持久性和最佳给药间隔是尚未解决的挑战。在这里,我们评估了长期的基因转移,转导和免疫反应后的AAV1载体编码Δ27-264 CFTR对幼年恒河猴单次肺管理。4只动物通过气管内喷雾获得1 × 101³载体基因组。其中两人未经治疗。所有患者在分娩后180天进行分析。在整个传导气道和远端肺中检测到载体基因组,其基因组DNA水平范围为~ 5 × 106至9 × 107 vg/µg。在肺外组织,包括肝脏、胰腺、脾脏、心脏和肾脏中也检测到载体基因组。囊性纤维化跨膜传导调节因子(CFTR)信使RNA在所有被检查组织以及几个呼吸和肺外组织中均有表达,同时在多个组织中CFTR蛋白表达升高。在气道基底细胞和foxi1阳性离子细胞中观察到转基因表达,表明靶向关键上皮细胞和祖细胞群。尽管载体基因组持续存在,免疫激活是有限的。细胞因子和趋化因子的表达谱仅显示零星的、组织特异性的变化,没有协调炎症的证据。在所有动物中,AAV1的中和抗体都产生,但与衣壳特异性T细胞反应无关,这种反应仍然很低且不常见。这些发现表明,在AAV1单次注射到灵长类动物肺部后,基因转移和转导持续至少180天,且免疫病理最小。表达的持久性支持延长给药间隔的潜在可行性,并为可重复的基于aav的CF基因治疗的发展提供了信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human gene therapy
Human gene therapy 医学-生物工程与应用微生物
CiteScore
6.50
自引率
4.80%
发文量
131
审稿时长
4-8 weeks
期刊介绍: Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书